Issue link: https://viewer.e-digitaledition.com/i/125960
A H IG H LY EFFEC TIVE TR E ATM ENT FO R N E AR LY 1 0 0 Y E ARS MOHS SURGERY ENABLES surgeons to precisely excise cancerous tissue while sparing healthy tissue, resulting in a cure rate of greater than 98% for basal cell carcinoma and squamous cell carcinoma. Mohs surgery can be performed on cancerous tissue anywhere on the body, but the procedure's tissue-sparing quality makes it particularly ideal for cancers of the head and neck. The Department of Medicine has opened a state-of-the-art Mohs surgery suite at Montefiore Medical Center's Division of Dermatology practice offices. The facility comprises three adjacent surgical suites and a laboratory for tissue processing, which affords surgeons an easy transition from tissue removal to processing. Surgeons use a cryostat machine to Dr. Packer and Nitin Ohri, M.D., review a PET/CT scan for a patient with melanoma. process and cut the tissue for placement on slides, which are then viewed under a microscope to ensure the removed tissue encapsulates all the cancerous tissue. Mohs is particularly useful in the treatment of recurrent cancers because it offers a higher cure rate. Specialists at Montefiore are able to evaluate the complete periphery — 360° around the skin cancer, including the depth of the skin cancer — to ensure it is entirely removed. Skin cancers that recur can be larger and potentially more aggressive, so Mohs is a great option. allow Dr. Ohri and his team to aggressively treat tumors while minimizing the exposure of healthy tissues to radiation, which in turn minimizes the side effects his patients experience during and after radiotherapy. In some cases, this also allows radiotherapy to be delivered during one to two weeks rather than the traditional five- to six-week course. Chemotherapy, Confined and Effective While chemotherapy may be an appropriate treatment option for other cancers that have spread beyond the point of origin, Dr. Packer says this is a lesser option for patients with melanoma. "One of the problems with melanoma is that it's in a group of cancers that have not been effectively treated with chemotherapy," Dr. Packer says. "Chemotherapy for metastatic melanoma is a very unsatisfying treatment because the cancer is not chemotherapy responsive. Treatment with chemotherapy is often associated with significant side effects, and to date, there has been no evidence it prolongs survival. In the past three years, there has been an explosion of information and knowledge about melanoma, and several effective treatments have been approved by the FDA." One treatment offered by Montefiore Einstein Center for Cancer Care's Melanoma/Sarcoma Program is isolated limb perfusion (ILP). For a local recurrence after adequate wide excision and in the absence of extraregional disease, surgery to remove the tumor is recommended. Approximately half of newly diagnosed cases of melanoma are isolated to the upper or lower limbs, and in as many as 10% of these cases, melanoma recurs in the same limb the primary diagnosis was made. For patients with recurrent melanoma that is confined to a limb and cannot be cured by surgical means, ILP can be offered. ILP provides an alternative to amputation. This method allows for large doses of chemotherapy to be delivered to the limb only, leaving the rest of the body unaffected. Montefiore is among a select group of medical centers nationwide to offer ILP and isolated limb infusion (ILI), Drs. Krishnamurthy and Papalezova review dermascopic features of a suspicious lesion. MDNEWS.COM I MD NEWS Lower Hudson/Bronx |9

